Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract Torres-Cornejo, A BenMarzouk-Hidalgo, OJ Viciana, P Sánchez, B López Ruz, Miguel Ángel López Cortes, LF Gutiérrez Valencia, A Human immunodeficiency virus 1 infection Human immunodeficiency virus 1 treatment Male genital tract Protease inhibitor monotherapy Triple therapy This project was supported by a grant from the Dirección Gerencia del Servicio Andaluz de Salud, Consejería de Salud, Junta de Andalucía (exp PI-0168-2012). Cross-sectional study comparing seminal human immunodeficiency virus type 1 (HIV-1) shedding in patients receiving boosted protease inhibitor monotherapy (mtPI/rtv) (n = 66) versus triple therapy (TT) (n = 61). Seminal HIV-1 shedding rates in patients with undetectable plasma HIV-RNA were 16.0% on mtPI/rtv compared with 28.6% on TT (p 0.173). Aviraemic status and time on viral suppression were independently associated with lack of seminal HIV-1 shedding. During TT, non PI/rtv-based regimens were associated with a better control of HIV infection in semen despite similar time on viral suppression. The use of mtPI/rtv in well-controlled patients is not associated with increased seminal HIV excretion compared with TT. 2024-04-22T07:15:26Z 2024-04-22T07:15:26Z 2015-10-08 journal article Torres-Cornejo et al. Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract. Clin Microbiol Infect . 2016 Jan;22(1):98.e7-98.e10. https://doi.org/10.1016/j.cmi.2015.09.028 https://hdl.handle.net/10481/90971 10.1016/j.cmi.2015.09.028 eng http://creativecommons.org/licenses/by-nc-nd/3.0/ open access Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License Elsevier